Solu Therapeutics develops therapies to selectively eliminate disease-driving cells in cancer and immunology, focusing on conditions like chronic myelomonocytic leukemia.

Somite Therapeutics leverages AI to develop cell therapies for diseases like diabetes and muscular dystrophies.

Shinobi Therapeutics is a biotech company developing off-the-shelf, immune-evasive, induced pluripotent stem cell (iPSC)-derived cell therapies for GPC3+ solid tumor cancers.